Page last updated: 2024-12-05

4-(4-nitrobenzyl)pyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID14129
CHEMBL ID1606980
SCHEMBL ID177812
MeSH IDM0052644

Synonyms (62)

Synonym
EU-0066581
AKOS000446143
CBMICRO_019234
OPREA1_403743
EN300-20019
HMS2625J17
4-(4-nitro-benzyl)-pyridine
smr000281726
MLS000711959 ,
einecs 214-108-2
4(4-nitrobenzyl)primide
gamma-(p-nitrobenzyl)pyridine
nsc 83591
brn 0170877
pyridine, 4-((4-nitrophenyl)methyl)-
1-(p-nitrobenzyl)pyridine
pyridine, 4-[(4-nitrophenyl)methyl]-
4-(4-nitrobenzyl)pyridine ,
1083-48-3
nsc-83591
pyridine, 4-(p-nitrobenzyl)-
nsc83591
4-(p-nitrobenzyl)pyridine
.gamma.-(p-nitrobenzyl)pyridine
.gamma.-(4-nitrobenzyl)pyridine
BIM-0019472.P001
inchi=1/c12h10n2o2/c15-14(16)12-3-1-10(2-4-12)9-11-5-7-13-8-6-11/h1-8h,9h
4-(4-nitrobenzyl)pyridine, 98%
NCIOPEN2_004508
STK396587
4-[(4-nitrophenyl)methyl]pyridine
N0183
A801862
NCGC00245125-01
0z6gs37n7h ,
5-20-07-00564 (beilstein handbook reference)
unii-0z6gs37n7h
CCG-7579
CHEMBL1606980
FT-0616656
bdbm94219
cid_14129
pyridine, 4-(p-nitrobenzyl)
4-((4-nitrophenyl)methyl)pyridine
4-(4'-nitrobenzyl)pyridine
SCHEMBL177812
11N-102
N-2587
DTXSID2061482
4-(4-nitrobenzyl)-pyridin
cambridge id 5373029
J-610027
4-[4-nitrobenzyl]pyridine
4-(4-nitrobenzyl)pyridine, for tlc derivatization, for spectrophotometric det. of phosphorus-containing pesticides
mfcd00006445
SR-01000596951-1
sr-01000596951
AMY23259
A51036
Q27251065
SB55064
SY070035

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" We believe that differences in PA metabolism and the nature of toxicity ultimately produced are in part related to differences in reactivity of the primary toxic intermediate, the DHA."( The relationship between reactivity of metabolites of pyrrolizidine alkaloids and extrahepatic toxicity.
Cooper, RA; Huxtable, RJ, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency22.38720.35487.935539.8107AID624170
DNA polymerase betaHomo sapiens (human)Potency39.81070.022421.010289.1251AID485314
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency17.78280.00419.962528.1838AID2675
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency25.99980.060110.745337.9330AID485367; AID504636; AID504637
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID633991Antifungal activity against Saccharomyces cerevisiae ATCC 24657 assessed as growth inhibition after 24 to 48 hrs by agar plate bioassay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (69)

TimeframeStudies, This Drug (%)All Drugs %
pre-199024 (34.78)18.7374
1990's15 (21.74)18.2507
2000's10 (14.49)29.6817
2010's18 (26.09)24.3611
2020's2 (2.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.55 (24.57)
Research Supply Index4.30 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.39%)5.53%
Reviews1 (1.39%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other70 (97.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]